Cramer’s lightning round: Editas Medicine is not a buy

Cramer’s lightning round: Editas Medicine is not a buy


DraftKings Inc: “They are in a battle, a pure battle to try to get market share and right now, there is no sign that the battle is over. … I do think they’ll win.”

SoFi Technologies Inc: “I can’t tell you to sell it. But I can also tell you, maybe I’m not the answer on this stock because holy cow, it hasn’t stopped [going down in price] and I thought it would have.”

Editas Medicine Inc: “You can not buy growth stocks that have no hope of making money. Not in this environment.”

Altria Group Inc: “It is tobacco, and that’s not what I’m fond of. … If you don’t care, then it’s fine.”



Source

NFL discussing media deal with Paramount that could mean CBS pays an extra  billion or more
Business

NFL discussing media deal with Paramount that could mean CBS pays an extra $1 billion or more

Roger Goodell, NFL Commissioner with Anthony Capuano, Marriott International CEO, CNBC CEO Council Member, speaking at the CNBC CEO Council in Arizona on May 19th, 2025. Chris Coduto | CNBC The NFL and Paramount Skydance‘s renewal talks on a deal to keep the league’s Sunday games on CBS are beginning to take shape, CNBC has […]

Read More
Mortgage rates surge to highest since September, hitting spring housing market
Business

Mortgage rates surge to highest since September, hitting spring housing market

In an aerial view, two-story single family homes line the streets of neighborhood on Jan. 13, 2026 in Thousand Oaks, California. Kevin Carter | Getty Images Mortgage rates surged to their highest level since September on Friday as bond yields moved higher due to the war in Iran. The average rate on the 30-year fixed […]

Read More
Blackstone is a major seller in January commercial real estate deals
Business

Blackstone is a major seller in January commercial real estate deals

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. After […]

Read More